46 results about "Insulin delivery" patented technology

In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and / or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and / or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.

Disclosed herein are apparatuses and methods that can provide a delayed bolus calculator for use in closed loop diabetes therapy that can account for additional factors not taken into account in regular meal bolus calculations when a user wants to deliver a meal bolus a period of time after a meal was consumed. A delayed bolus calculator can enable the user to enter a period of time since the meal was consumed in addition to the number of carbohydrates consumed in a meal. This enables the system to account for the amount of increased insulin from the closed loop algorithm in response to the meal and / or the time since the meal to ensure that the risk of hypoglycemia is mitigated while still reducing hyperglycemia.

Techniques disclosed herein related to controlling insulin delivery. In some embodiments, the techniques may involve delivering insulin via an insulin infusion device according to a closed-loop mode of delivery. The techniques may further involve determining, at a first time point, insulin delivery is to be switched from the closed-loop mode of delivery to a second mode of delivery. The techniques may further involve switching operation of the insulin infusion device to the second mode of delivery such that insulin is delivered via the insulin infusion device according to the second mode of delivery.

A diabetes management system optimizes glucoregulatory hormone delivery using a connected glucoregulatory hormone delivery system and a computing device with a processor and non-transitory memory. The system receives glucose management data (glucose, insulin delivery, heart rate, or carbohydrate consumption data) from sensors. A digital twin metabolic model is selected and initialized based on the received data. The system simulates diabetes treatment interventions to predict glucose dynamics and determines an optimized glucoregulatory hormone parameter (e.g., insulin dose or increment that minimizes hyperglycemia and hypoglycemia risk). The determined glucoregulatory hormone parameter is transmitted to the connected glucoregulatory hormone delivery system, which may include an automated insulin delivery (AID) system or a connected insulin pen system, for implementation. By integrating real-time physiological data with predictive metabolic modeling, the system enhances glucoregulatory hormone therapy, providing personalized adjustments to improve glucose control.

The invention belongs to the technical field of medical biological dressings, and provides a composite dressing with oxygen release and insulin delivery functions and a preparation method thereof.The composite dressing comprises a supporting base layer, a function slow release layer and a protective film layer which are sequentially compounded from bottom to top; the supporting base layer is a medical porous polyurethane film modified by plasma; the functional sustained release layer is composed of hyaluronic acid-chitosan composite gel, oxygen release microspheres and insulin liposome; the protective film layer is a polyethylene terephthalate film of which the surface is provided with a sawtooth edge easy to tear; through an integrated three-layer patch structure, by combining the synergistic effect of PLGA microsphere controlled-release oxygen, liposome low-molecular chitosan insulin delivery and gel matrix, the skin injury microenvironment is effectively improved, inflammation is inhibited, and the healing time is shortened.

An insulin delivery system for diabetes management includes a patch-based insulin pump configured to deliver insulin to a user, a user input button disposed on the patch-based insulin pump, a processor configured to execute a hybrid closed loop algorithm that automatically controls insulin delivery based on glucose levels. The user input button is configured to receive user input comprising a sequence of button presses that communicate contextual information about user activities to the hybrid closed loop algorithm, the contextual information being distinct from direct insulin bolus delivery commands. The contextual information may include meal intake, physical activity, and sleep status communicated through different sequences of button presses. The system includes confirmation mechanisms that provide feedback and allow cancellation of inputs, enabling discrete real-time communication of personalized data to enhance diabetes management.

The application discloses a glucose-responsive insulin delivery system and a preparation method and application thereof, and belongs to the technical field of biomaterials. The glucose-responsive insulin delivery system provided by the application comprises a delivery carrier and a bioactive component encapsulated in the carrier; the delivery carrier is a metal polyphenol network formed by a coordination reaction between epigallocatechin gallate and metal ions; and the bioactive component comprises glucose oxidase, catalase and insulin. The glucose-responsive insulin delivery system can adjust the release of insulin according to the concentration of glucose in the surrounding environment, so that the blood glucose can be maintained at a normal level.

Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.

A method of improving insulin delivery includes detecting a dosing event of an upcoming insulin dose, identifying a next injection site to recommend to a user for the upcoming insulin dose, and transmitting a recommended injection site to a delivery device to be displayed on the delivery device. The method further includes receiving a user selection of a plurality of injection sites to include within an injection site recommendation profile, receiving a user selection of an injection cycle to utilize within the injection site recommendation profile, and generating an injection site recommendation profile.

Systems and methods are disclosed for managing a person's blood glucose concentration within a predetermined range by co-administration of insulin and pramlintide using an automated insulin delivery system. A model predictive control (MPC) algorithm that includes a glucoregulatory control model augmented with a compartment model of pramlintide pharmacokinetics and pharmacodynamics is utilized. In some embodiments, the person may announce in advance meals to be consumed and the pramlintide-aware MPC algorithm uses this data as input to the glucoregulatory control model. In other embodiments, an automatic meal detection and size estimation algorithm is incorporated into the system to relieve the person of the burden of meal entry and carbohydrate estimation.

The disclosed embodiments are directed to methods for dynamically adjusting the total daily insulin requirements of a user during pregnancy, based on the gestational week. An initial estimate of the adjusted total daily insulin requirement may be calculated as a multiple of the pre-pregnancy total daily insulin requirement, based on an average scale factor from a population of pregnant women suffering from Type I diabetes mellitus. An automatic drug delivery device may adjust the initial estimate of the total daily insulin requirement based on blood glucose level readings from a continuous glucose monitor during the course of the pregnancy.

The invention relates to the technical field of medical equipment, and discloses a diabetic insulin infusion device which comprises a mounting shell, a medicine storage shell is fixedly mounted in the middle of the top end of the mounting shell, a containing cavity used for containing insulin is formed in the medicine storage shell, and a protective shell is detachably connected to one side of the top of the mounting shell; a driving motor is fixedly mounted on the inner side of the protective shell, a fixed seat is fixedly connected to the inner bottom wall of the capacity cavity, a movable rod is slidably connected to an inner through hole of the fixed seat, a rotating shaft is movably connected to the interior of the capacity cavity through a bearing, and a driving part is fixedly connected to the middle side of the exterior of the rotating shaft; and the inner side of the driving piece is rotationally connected with a hinge rod. Through the targeted anti-blocking design, the continuity and smoothness of insulin delivery in the infusion tube can be continuously guaranteed, abnormal blood glucose fluctuation caused by infusion interruption and the risk of hypoglycemia caused by blind supplementary infusion after blockage is removed are avoided, and the stability and accuracy of insulin infusion are remarkably improved.

The exemplary embodiments provide an automated approach for adjusting the medicament delivery rate to the user when operating in an open loop manner (“open mode”). The approach relies upon an insulin delivery history to the user make adjustments to the medicament delivery rate in the open mode. In particular, the exemplary embodiments may look at the medicament delivery history while the medicament delivery device is operating in a closed loop manner (“closed mode”) to determine how to adjust the open mode medicament delivery rate. It is presumed that in closed mode, the control system of the medicament device has gained knowledge over time about how to control the medicament delivery rate to produce good treatment outcomes for the user. The exemplary embodiments leverage this knowledge to adjust the open mode medicament delivery rates. Medicament bolus deliveries in open mode may also be adjusted in like fashion.

A control device for managing insulin delivery in a closed-loop system. The control device comprises a computation module. The computation module is configured to receive a target basal rate indicative of a rate of a target insulin delivery rate of an insulin pump and compute a supplemental basal rate if the target basal rate is greater than a rate threshold. The supplemental basal rate is sensibly equal to a difference between the target basal rate and the rate threshold. The control device also comprises an insulin management module. The insulin management module is configured to determine a recommendation value of a control parameter of the insulin pump. The recommendation value is based on the supplemental basal rate multiplied by a time period. The control device comprises a communication module. The communication module is configured to send the recommendation value to the insulin pump.

Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.

An infusion system is disclosed comprising: a device for delivering insulin to a user, the device including a reservoir and a micropump for pumping the insulin from the reservoir into tissue of a user; and a cartridge for securing a cartridge insert that includes (a) an infusion needle configured to infuse the insulin and introduce a CGM sensor into the user or (b) an introducer needle for introducing an infusion catheter and the CGM sensor into the user, the cartridge configured to move from (1) a first position, wherein the infusion needle or an introducer needle is above the tissue of the user to (2) an second position, wherein the infusion needle or the introducer needle is in a deployed position inserted into tissue of the user, wherein the cartridge includes a locking mechanism to lock the cartridge insert into the cartridge.

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include adjusting user specific dosage parameters in response to one or more back-filled time segments associated with a diurnal time block.

Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

Methods and apparatuses for performing an insulin infusion process are described. For example, an apparatus may include at least one memory and logic coupled to the at least one memory. The logic may operate to determine a basal parameter for a patient based on a type 2 diabetes (T2D) multiple daily injection (MDI) information of the patient, the basal parameter indicating a basal infusion rate, determine an additional insulin (Iadd) value based on a mean blood glucose difference (BGdiff) information associated with the patient, determine an insulin volume to infuse into the patient based on the basal parameter and Iadd, and administer the insulin volume to the patient. Other embodiments are described.

The application belongs to the technical field of medical devices, and particularly relates to a double closed loop insulin delivery system, application thereof and a medical product. The application discloses a double closed loop insulin delivery system, and particularly comprises a dynamic blood glucose monitoring system, a double closed loop control algorithm, an insulin pump and specific sugar response insulin analogues. The application controls blood glucose in a double closed loop mode, can realize a high proportion of time of blood glucose in a target range, realizes more stable, safe and simple blood glucose control, and does not need human intervention in the use process of the system, and provides a more intelligent and humanized treatment scheme for diabetic patients.

The disclosed embodiments are directed to methods for dynamically adjusting the total daily insulin requirements of a user during pregnancy, based on the gestational week. An initial estimate of the adjusted total daily insulin requirement may be calculated as a multiple of the pre-pregnancy total daily insulin requirement, based on an average scale factor from a population of pregnant women suffering from Type I diabetes mellitus. An automatic drug delivery device may adjust the initial estimate of the total daily insulin requirement based on blood glucose level readings from a continuous glucose monitor during the course of the pregnancy.

A system for managing a patient's glucose level includes a glucose sensor to generate and store data signals for measurements of the patient's glucose level made by the glucose sensor; an insulin pump; and sensor electronics operatively coupled to the glucose sensor, the sensor electronics comprising a memory storing one or more predetermined characteristics associated with the sensor electronics; and a computing device in electronic communication with the sensor electronics. The computing device comprises a processor configured to operate the sensor electronics to (i) receive the generated data signals, (ii) obtain the one or more predetermined sensor characteristics from the memory and (iii) execute a closed-loop algorithm to provide insulin delivery instructions to an insulin pump by at least using the data signals and predetermined characteristics.

Systems, methods, and devices are provided for predicting a status of an infusion site. Approaches include applying a regression model to physiological glucose data and insulin delivery data to generate predictive data, operating a trained machine learning model to process the predictive data to generate an output, and determining that the infusion site has failed or is likely to have failed based on the output.

A system for managing a patient's glucose level includes a glucose sensor to generate and store data signals for measurements of the patient's glucose level made by the glucose sensor; an insulin pump; and sensor electronics operatively coupled to the glucose sensor, the sensor electronics comprising a memory storing one or more predetermined characteristics associated with the sensor electronics; and a computing device in electronic communication with the sensor electronics. The computing device comprises a processor configured to operate the sensor electronics to (i) receive the generated data signals, (ii) obtain the one or more predetermined sensor characteristics from the memory and (iii) execute a closed-loop algorithm to provide insulin delivery instructions to an insulin pump by at least using the data signals and predetermined characteristics.

A pharmaceutical composition is disclosed comprising an insulin, a set of excipients, and a penetration enhancer, wherein the penetration enhancer is a prostaglandin analogue configured to enhance the permeability of insulin upon topical ocular administration. The composition enables increased transport of insulin across ocular tissues, improving absorption and bioavailability following topical delivery to the eye. The formulation includes pharmaceutically acceptable excipients such as surfactants, buffering agents, viscosity enhancers, tonicity agents, preservatives, and solvents suitable for ophthalmic use. The invention provides a non-invasive route of administering insulin through the eye, allowing systemic or local therapeutic effects without injection.

Disclosed herein are systems and methods for automated insulin delivery that provide for adaptive closed loop control that can modify the stored basal profile used by the closed loop algorithm to better reflect the user's actual needs. Actual delivery rates calculated by the closed loop algorithm can be compared to the user's stored profile. If the differences between the actual delivery rates and the stored profile are statistically significant, the stored profile can be modified.